PATHFINDER 2 Results: What the Galleri Multi-Cancer Blood Test Actually Found
Dr. Dereck Mush, MD, MBA
Freenome
Develops blood tests for early cancer detection using genomics and machine learning.
What they do
Freenome builds non-invasive blood tests designed to detect cancer at its earliest, most treatable stages. Utilizing a multiomics platform that combines genomic, proteomic, and computational biology, the company helps health systems and clinicians screen for colorectal and other cancers.
The record
- Vertical
- Oncology
- Sub-segment
- Early cancer detection
- Product type
- Diagnostics
- Stage
- Series C+
- Headquarters
- South San Francisco, United States
- Region
- North America
- Founded
- 2014
- Total funding
- $1.4B raised
Notable investors: Roche, Andreessen Horowitz, Bain Capital Life Sciences, Perceptive Advisors.
Also in Oncology
Related on The Signal
Dr. Dereck Mush, MD, MBA
The MCED Inflection Point: What Galleri's FDA Panel Backing Means for Cancer Screening
Dr. Dereck Mush, MD, MBA
Beyond HER2 and TROP2: How AbbVie's c-Met Top1i Antibody-Drug Conjugate Earned Two Breakthrough Designations
Dr. Dereck Mush, MD, MBA
Doctors Read Her Mammogram and Saw Nothing. The AI Saw a Tumor.
Dr. Dereck Mush, MD, MBA